International Journal of Endocrinology and Metabolism

Published by: Kowsar

The Role of Estrogen in the Treatment of Men with Schizophrenia

Jayashri Kulkarni 1 , * , Emmy Gavrilidis 1 , Roisin Worsley 1 , Tamsyn Van Rheenen 1 and Emily Hayes 1
Authors Information
1 The Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, Australia
Article information
  • International Journal of Endocrinology and Metabolism: July 01, 2013, 11 (3); 129-136
  • Published Online: July 1, 2013
  • Article Type: Review Article
  • Received: June 1, 2012
  • Revised: August 20, 2012
  • Accepted: September 28, 2012
  • DOI: 10.5812/ijem.6615

To Cite: Kulkarni J, Gavrilidis E, Worsley R, Van Rheenen T, Hayes E. The Role of Estrogen in the Treatment of Men with Schizophrenia, Int J Endocrinol Metab. 2013 ; 11(3):129-136. doi: 10.5812/ijem.6615.

Copyright © 2013, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Gender Differences in Schizophrenia Symptoms and Course of Illness
3. Psychoprotective Properties of Estrogens
4. Concerns Regarding the Use of Estradiol in Men
5. Selective Estrogen Receptor Modulators
6. Conclusions
  • 1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV-TR. 2000;
  • 2. Jablensky AV, McGrath J, Herrman H, Castle D, Gureje O, Evans M. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry. [Research Support, Non-U.S. Gov't]. 2000; 34(2): 221-36
  • 3. Carr Vaughan J, Neil Amanda L, Halpin Sean A, Holmes Scott, Lewin Terry J. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Australas Psychiat. 2003; 37(1): 31-40
  • 4. Kraepelin E. Psychiatrie; ein Lehrbuch für Studierende und Ärzte. 1910;
  • 5. Krafft-Ebing G. Untersuchungen über Irresein zur Zeit der Menstruation: ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch Psychiatry. 1896; 8: 65-107
  • 6. Häfner Heinz. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003; 28: 17-54
  • 7. Kulkarni Jayashri. Women and schizophrenia: a review. Australas Psychiat. 1997; 31(1): 46-56
  • 8. Riecher-Rössler Anita, Häfner Heinz. Schizophrenia and oestrogens—is there an association? Eur Arch Psy Clin N. 1993; 242(6): 323-328
  • 9. Seeman Mary V, Lang Marisa. The role of estrogens in schizophrenia gender differences. Schizophrenia Bull. 1990; 16(2): 185-194
  • 10. Akhondzadeh Shahin, Nejatisafa Ali Akbar, Amini Homayoun, Mohammadi Mohammad Reza, Larijani Bagher, Kashani Ladan, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuro-Psychopha Bio Psychiatry . 2003; 27(6): 1007-1012
  • 11. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008; 65(8): 955-60[DOI][PubMed]
  • 12. Kulkarni J, Gavrilidis E, Worsley R, Hayes E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs. 2012; 26(7): 549-57[DOI][PubMed]
  • 13. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008; 30: 67-76[DOI][PubMed]
  • 14. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007; 64(1): 19-28[DOI][PubMed]
  • 15. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003; 60(6): 565-71[DOI][PubMed]
  • 16. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004; 2: 13[DOI][PubMed]
  • 17. Angermeyer Matthias C, Kühnz Ludwig. Gender differences in age at onset of schizophrenia. Eur Arch Psy Neurol Sci. 1988; 237(6): 351-364
  • 18. Faraone SV, Chen WJ, Goldstein JM, Tsuang MT. Gender differences in age at onset of schizophrenia. Br J Psychiatry. 1994; 164(5): 625-9[PubMed]
  • 19. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med. 2007; 37(10): 1427-36[DOI][PubMed]
  • 20. Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res. 2010; 124(1-3): 13-21[DOI][PubMed]
  • 21. Hafner H, Nowotny B, Loffler W, an der Heiden W, Maurer K. When and how does schizophrenia produce social deficits? Eur Arch Psychiatry Clin Neurosci. 1995; 246(1): 17-28[PubMed]
  • 22. Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD, et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res. 2009; 114(1-3): 17-24[DOI][PubMed]
  • 23. Beratis S, Gabriel J, Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr Bull. 1994; 20(2): 287-96[PubMed]
  • 24. Goldstein Jill M, Link Bruce G. Gender and the expression of schizophrenia. J Psychiat Res. 1988; 22(2): 141-155[DOI]
  • 25. Dopfner M, Pluck J, Berner W, Fegert JM, Huss M, Lenz K, et al. [Mental disturbances in children and adolescents in Germany. Results of a representative study:age,gender and rater effects]. Z Kinder Jugendpsychiatr Psychother. 1997; 25(4): 218-33[PubMed]
  • 26. Morgan VA, Castle DJ, Jablensky AV. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. Aust N Z J Psychiatry. 2008; 42(1): 74-82[DOI][PubMed]
  • 27. Gómez-de-Regil Lizzette, Kwapil Thomas R, Blanqué Joan Manel, Vainer Elias, Montoro Mónica, Barrantes-Vidal Neus. Predictors of outcome in the early course of first-episode psychosis. Eur J Psychiat. 2010; 24(2): 87-97
  • 28. Cosimo Melcangi R, Garcia-Segura LM. Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection. Horm Behav. 2010; 57(1): 2-11[DOI][PubMed]
  • 29. McEwen BS. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol. 2001; 91(6): 2785-801[PubMed]
  • 30. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology. 2005; 30(4): 309-15[DOI][PubMed]
  • 31. Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. Int J Gynecol Obstet. 1999; 65(1): 35-38
  • 32. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000; 183(2): 414-20[DOI][PubMed]
  • 33. Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, et al. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alzheimers Dis. 2011; 26(3): 495-505[DOI][PubMed]
  • 34. Yonker JE, Adolfsson R, Eriksson E, Hellstrand M, Nilsson LG, Herlitz A. Verified hormone therapy improves episodic memory performance in healthy postmenopausal women. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2006; 13(3-4): 291-307[DOI][PubMed]
  • 35. Österlund Marie K, Hurd Yasmin L. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol. 2001; 64(3): 251-267
  • 36. Roberts Angela C, Robbins Trevor W, Weiskrantz Lawrence. The prefrontal cortex Executive and cognitive functions. 1998;
  • 37. Gonzalez M, Cabrera-Socorro A, Perez-Garcia CG, Fraser JD, Lopez FJ, Alonso R, et al. Distribution patterns of estrogen receptor alpha and beta in the human cortex and hippocampus during development and adulthood. J Comp Neurol. 2007; 503(6): 790-802[DOI][PubMed]
  • 38. Litwack G. Hormones of the Limbic System. 2010;
  • 39. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol. 1996; 16(3): 325-44[PubMed]
  • 40. Hafner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci. 1991; 241(1): 65-8[PubMed]
  • 41. Halbreich Uriel, Rojansky Nathan, Palter Steven, Tworek Henry, Hissin Paul, Wang Ke. Estrogen augments serotonergic activity in postmenopausal women. Biological psychiatry. 1995; 37(7): 434-441
  • 42. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001; 15(10): 797-817[PubMed]
  • 43. Halbreich Uriel. Role of estrogen in postmenopausal depression. Neurology. 1997; 48(5 Suppl 7): 16S-20S
  • 44. Hiroi Ryoko, McDevitt Ross A, Neumaier John F. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiat. 2006; 60(3): 288-295
  • 45. Bethea Cynthia L, Mirkes Stephanie J, Shively Carol A, Adams Michael R. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiat. 2000; 47(6): 562
  • 46. Pecins-Thompson M, Brown NA, Kohama SG, Bethea CL. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci. 1996; 16(21): 7021-9[PubMed]
  • 47. Ivanova T, Beyer C. Estrogen regulates tyrosine hydroxylase expression in the neonate mouse midbrain. J Neurobiol. 2003; 54(4): 638-47[DOI][PubMed]
  • 48. Sawada Hideyuki, Ibi Masakazu, Kihara Takeshi, Honda Kazuhiro, Nakamizo Tomoki, Kanki Rie, et al. Estradiol protects dopaminergic neurons in a MPP+ Parkinson’s disease model. Neuropharmacology. 2002; 42(8): 1056-1064
  • 49. Lyons Kelly E, Hubble Jean P, Tröster Alexander I, Pahwa Rajesh, Koller William C. Gender differences in Parkinson's disease. Clinical neuropharmacology. 1998; 21(2): 118-121
  • 50. Wolfe Nicola, Katz DI, Albert ML, Almozlino A, Durso R, Smith MC, et al. Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease. J Neurol Neurosurgery Psychiat. 1990; 53(10): 915-917
  • 51. Wharton Whitney, Baker Laura D, Gleason Carey E, Dowling Maritza, Barnet Jodi H, Johnson Sterling, et al. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alz Dis. 2011; 26(3): 495-505
  • 52. Henderson Victor W, Paganini-Hill Annlia, Emanuel Christina K, Dunn Meleana E, Buckwalter J Galen. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994; 51(9): 896
  • 53. Fernandez Hubert H, Lapane Kate L. Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Movement disorders. 2000; 15(6): 1119-1124
  • 54. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson’s disease. Neurology. 1999; 52(7): 1417-1417
  • 55. Tang Ming-Xin, Jacobs Diane, Stern Yaakov, Marder Karen, Schofield Peter, Gurland Barry, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. The Lancet. 1996; 348(9025): 429-432
  • 56. Paganini-Hill Annlia, Henderson Victor W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994; 140(3): 256-261
  • 57. Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A. 2005; 102(52): 19198-203[DOI][PubMed]
  • 58. Kawas Claudia, Resnick S, Morrison AMRC, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease The Baltimore Longitudinal Study of Aging. Neurology. 1997; 48(6): 1517-1521
  • 59. Hampson Elizabeth. Estrogen-related variations in human spatial and articulatory-motor skills. Psychoneuroendocrinology. 1990; 15(2): 97-111
  • 60. Kulkarni J. Oestrogen--a new treatment approach for schizophrenia? Med J Aust. 2009; 190(4 Suppl)-8[PubMed]
  • 61. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003; 28: 1-16
  • 62. Kulkarni J, Riedel A, De Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, et al. Estrogen—a potential treatment for schizophrenia. Schizophr Res. 2001; 48(1): 137-144
  • 63. Kulkarni Jayashri, Garland Kathryn A, Scaffidi Antonietta, Headey Barbara, Anderson Robyn, de Castella Anthony, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology. 2006; 31(4): 543
  • 64. Hafner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission: evidence from an epidemiological study and from animal experiments. Eur Arch Psy Clin Neurosci. 1991; 241(1): 65-68
  • 65. Häfner Heinz, an der Heiden Wolfram, Behrens Stephan, Gattaz Wagner F, Hambrecht Martin, Löffler Walter, et al. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophrenia Bull. 1998; 24(1): 99-113
  • 66. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1(2): 133-52[DOI][PubMed]
  • 67. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl. 2007; (434): 41-9[DOI][PubMed]
  • 68. Mahmood Tariq, Silverstone Trevor. Serotonin and bipolar disorder. J Affect Disorders. 2001; 66(1): 1-11
  • 69. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2007;
  • 70. Urosevic S, Abramson LY, Harmon-Jones E, Alloy LB. Dysregulation of the behavioral approach system (BAS) in bipolar spectrum disorders: review of theory and evidence. Clin Psychol Rev. 2008; 28(7): 1188-205[DOI][PubMed]
  • 71. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry. 2009; 195(6): 475-82[DOI][PubMed]
  • 72. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006; 67(10)[PubMed]
  • 73. Green Michael Foster, Nuechterlein Keith H. Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bull. 1999; 25(2): 309-319
  • 74. Hooker C, Park S. Emotion processing and its relationship to social functioning in schizophrenia patients. Psychiatry Res 2002; 112(1): 41-50
  • 75. Getz GE, Shear PK, Strakowski SM. Facial affect recognition deficits in bipolar disorder. J Int Neuropsychol Soc. 2003; 9(4): 623-32[DOI][PubMed]
  • 76. Riecher-Rossler A, Hafner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull. 1994; 20(1): 203-14[PubMed]
  • 77. Ko YH, Joe SH, Cho W, Park JH, Lee JJ, Jung IK, et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology. 2006; 53(4): 169-75[DOI][PubMed]
  • 78. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, et al. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry. 2001; 158(7): 1134-9[PubMed]
  • 79. Hogervorst Eva, De Jager Celeste, Budge Marc, Smith A David. Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology. 2004; 29(3): 405-421
  • 80. Senanarong V, Vannasaeng S, Poungvarin N, Ploybutr S, Udompunthurak S, Jamjumras P, et al. Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Arch Neurol. 2002; 59(3): 385-9[PubMed]
  • 81. Yaffe K, Barnes D, Lindquist K, Cauley J, Simonsick EM, Penninx B, et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging. 2007; 28(2): 171-178
  • 82. Kampen Diane L, Sherwin Barbara B. Estradiol is related to visual memory in healthy young men. Behav Neurosci. 1996; 110(3): 613
  • 83. E Carlson Linda, B Sherwin Barbara. Steroid hormones, memory and mood in a healthy elderly population. Psychoneuroendocrinology. 1998; 23(6): 583-603
  • 84. Geerlings MI, Launer LJ, de Jong FH, Ruitenberg A, Stijnen T, van Swieten JC, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol. 2003; 53(5): 607-15[DOI][PubMed]
  • 85. Young LA, Neiss MB, Samuels MH, Roselli CE, Janowsky JS. Cognition is not modified by large but temporary changes in sex hormones in men. J Clin Endocrinol Metab. 2010; 95(1): 280-8[DOI][PubMed]
  • 86. Geerlings MI, Strozyk D, Masaki K, Remaley AT, Petrovitch H, Ross GW, et al. Endogenous sex hormones, cognitive decline, and future dementia in old men. Ann Neurol. 2006; 60(3): 346-55[DOI][PubMed]
  • 87. Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000; 12(3): 407-14[PubMed]
  • 88. Almeida OP, Yeap BB, Hankey GJ, Jamrozik K, Flicker L. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008; 65(3): 283-9[DOI][PubMed]
  • 89. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006; 91(11): 4335-43[DOI][PubMed]
  • 90. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004; 61(2): 162-7[DOI][PubMed]
  • 91. Seidman SN, Araujo AB, Roose SP, Devanand DP, Xie S, Cooper TB, et al. Low testosterone levels in elderly men with dysthymic disorder. Am J Psychiatry. 2002; 159(3): 456-9[PubMed]
  • 92. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol. 2006; 155(6): 773-81[DOI][PubMed]
  • 93. Beer Tomasz M, Bland Lisa B, Bussiere Joseph R, Neiss Michelle B, Wersinger Emily M, Garzotto Mark, et al. Testosterone loss and estradiol administration modify memory in men. J Urology. 2006; 175(1): 130-135
  • 94. Wang Christina, Cunningham Glenn, Dobs Adrian, Iranmanesh Ali, Matsumoto Alvin M, Snyder Peter J, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocr Metab. 2004; 89(5): 2085-2098
  • 95. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001; 57(1): 80-8[PubMed]
  • 96. Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem. 2001; 77(5): 1319-26[PubMed]
  • 97. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003; 6(1): 13-7[PubMed]
  • 98. Fernandez-Egea Emilio, García-Rizo Clemente, Miller Brian, Parellada Eduard, Justicia Azucena, Bernardo Miguel, et al. Testosterone in newly diagnosed, antipsychotic-naive men with nonaffective psychosis: a test of the accelerated aging hypothesis. Psychosom Med. 2011; 73(8): 643-647
  • 99. Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non‐metastatic prostate cancer. Psycho‐Oncology. 2009; 18(3): 237-247
  • 100. Almeida Osvaldo P, Waterreus Anna, Spry Nigel, Flicker Leon, Martins Ralph N. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004; 29(8): 1071-1081[DOI]
  • 101. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002; 57(5)-5[PubMed]
  • 102. Oberlander Joseph G, Schlinger Barney A, Clayton Nicola S, Saldanha Colin J. Neural aromatization accelerates the acquisition of spatial memory via an influence on the songbird hippocampus. Horm Behav. 2004; 45(4): 250-258
  • 103. Naghdi Nasser, Oryan Shahrbanoo, Etemadi Roshanak. The study of spatial memory in adult male rats with injection of testosterone enanthate and flutamide into the basolateral nucleus of the amygdala in Morris water maze. Brain research. 2003; 972(1): 1-8
  • 104. Fink George, Sumner Barbara, Rosie Roberta, Wilson Helen, McQueen Judith. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res. 1999; 105(1): 53
  • 105. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005; 64(2): 290-6[DOI][PubMed]
  • 106. Wolf Oliver T, Kirschbaum Clemens. Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Horm Behav. 2002; 41(3): 259-266
  • 107. Miles Clare, Green Richard, Sanders Geoff, Hines Melissa. Estrogen and memory in a transsexual population. Horm Behav. 1998; 34(2): 199-208
  • 108. Carlson Linda E, Sherwin Barbara B, Chertkow Howard M. Relationships Between Mood and Estradiol (E~ 2) Levels in Alzheimers's Disease (AD) Patients. J Gerontol Ser B. 2000; 55(1)
  • 109. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past? J Urol. 2003; 169(5): 1735-7[DOI][PubMed]
  • 110. Spetz Anna-Clara, Hammar Mats, Lindberg Bengt, Spångberg Anders, Varenhorst Eberhard. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J urol. 2001; 166(2): 517-520
  • 111. Hedlund Per Olov, Henriksson Peter. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology. 2000; 55(3): 328-332
  • 112. Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S, et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res. 2011; 125(2-3): 278-83[DOI][PubMed]
  • 113. Kyomen HH, Hennen J, Gottlieb GL, Wei JY. Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia. Am J Psychiatry. 2002; 159(7): 1225-7[PubMed]
  • 114. Kyomen HH, Satlin A, Hennen J, Wei JY. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial. Am J Geriatr Psychiatry. 1999; 7(4): 339-48[PubMed]
  • 115. Kulkarni J, De Castella A, Taffe J. Clinical adjunctive estrogen trial in men with schizophrenia: a pilot study. Schizophr Res. 1999; 36: 286
  • 116. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011; 164(4): 635-42[DOI][PubMed]
  • 117. Sherwin Barbara B, Chertkow Howard, Schipper Hyman, Nasreddine Ziad. A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging. 2011; 32(10): 1808-1817
  • 118. Livio M, Mannucci PM, Vigano G, Mingardi G, Lombardi R, Mecca G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986; 315(12): 731-5[DOI][PubMed]
  • 119. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF, Jr. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000; 85(9): 3027-35[PubMed]
  • 120. Comhaire FH, Dhooge W, Mahmoud A, Depuydt C. [A strategy for the prevention of male infertility]. Verh K Acad Geneeskd Belg. 1999; 61(3): 441-52[PubMed]
  • 121. Lidegaard Øjvind, Løkkegaard Ellen, Svendsen Anne Louise, Agger Carsten. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339
  • 122. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281(23): 2189-97[PubMed]
  • 123. Mosca L. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann N Y Acad Sci. 2001; 949: 181-5[PubMed]
  • 124. Vogel Victor G, Costantino Joseph P, Wickerham D Lawrence, Cronin Walter M, Wolmark Norman. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clinical breast cancer. 2002; 3(2): 153-159
  • 125. Lidegaard Øjvind, Løkkegaard Ellen, Jensen Aksel, Skovlund Charlotte Wessel, Keiding Niels. Thrombotic stroke and myocardial infarction with hormonal contraception. New Engl J Med. 2012; 366(24): 2257-2266
  • 126. Cummings Steven R, Ettinger Bruce, Delmas Pierre D, Kenemans Peter, Stathopoulos Victoria, Verweij Pierre, et al. The effects of tibolone in older postmenopausal women. New Engl J Med. 2008; 359(7): 697-708
  • 127. Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric. 2012; 15(3): 229-234
  • 128. Messalli EM, Scaffa C. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health. 2010; 1: 11-20[PubMed]
  • 129. Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, Castle D. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry. 2012; 46(9): 851-63[DOI][PubMed]
  • 130. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res Paediatr. 2008; 48(4): 155-163
  • 131. Goldstein Steven R, Scheele Wim H, Rajagopalan Srikanth K, Wilkie Jennifer L, Walsh Brian W, Parsons Anna K. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstetrics and Gynecology. 2000; 95(1): 95-103
  • 132. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7): 637-45[PubMed]
  • 133. Huang Y, Huang YL, Lai B, Zheng P, Zhu YC, Yao T. Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of high-voltage-activated calcium current. Neuroscience. 2007; 147(2): 334-41[DOI][PubMed]
  • 134. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 2002; 8(3): 309-30[PubMed]
  • 135. Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology. 2007; 27(6): 604-8[DOI][PubMed]
  • 136. Kulkarni Jayashri, Gurvich Caroline, Lee Stuart J, Gilbert Heather, Gavrilidis Emmy, de Castella Anthony, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology. 2010; 35(8): 1142-1147
  • 137. Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci. 2002; 27(1): 12-27[PubMed]
  • 138. Wu Xin, Glinn Michele A, Ostrowski Nancy L, Su Yuan, Ni Binhui, Cole Harlan W, et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain research. 1999; 847(1): 98-104
  • 139. Yaffe Kristine, Krueger Kathryn, Cummings Steven R, Blackwell Terri, Henderson Victor W, Sarkar Somnath, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005; 162(4): 683-690
  • 140. Nickelsen Thomas, G Lufkin Edward, Lawrence Riggs B, A Cox David, H Crook Thomas. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology. 1999; 24(1): 115-128
  • 141. Gleason CE, Baker LD, Chlerton B, Craft S, Cherrier M, Lofgreen T. Effects of raloxifene on verbal memory in women with Alzheimer's disease. Abstracts of the Society for Neuroscience. 2001; : 1449
  • 142. Asthana S. Estrogen and cognition: a true relationship? J Am Geriatr Soc. 2004; 52(2): 316-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments